Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters








Database
Language
Publication year range
1.
Clin Neuropharmacol ; 38(3): 104-8, 2015.
Article in English | MEDLINE | ID: mdl-25970278

ABSTRACT

BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating condition with high mortality. Proper management of this complex disease requires early surgical intervention followed by medical therapy. Pharmacological agents that unequivocally improve outcomes in aSAH are scarce. METHODS: The authors performed an exhaustive query of several databases including MEDLINE, the CENTRAL Register of Controlled Trials, and the Cochrane Database of Systematic Reviews for specific evidence on key medications that have been used in the treatment of aSAH. RESULTS: The bulk of the data available pertained to the following medications: calcium channel blockers, magnesium, statins, antifibrinolytics, aspirin, glucocorticoids, clazosentan, and tirilazad. Except for calcium channel blockers, the authors could not find any hard evidence that any of these agents affected outcome to a tangible degree. Aspirin may have some promise in prevention of aneurysm rupture and incidence of aSAH, but more substantive data are needed to conclusively corroborate this. CONCLUSIONS: Investigational efforts to attain outcome-modifying agents have had dubious results, but the inquest for discovery should not discontinue.


Subject(s)
Calcium Channel Blockers/therapeutic use , Intracranial Aneurysm/complications , Subarachnoid Hemorrhage/drug therapy , Subarachnoid Hemorrhage/prevention & control , Aspirin/therapeutic use , Humans , Subarachnoid Hemorrhage/etiology , Treatment Failure , Treatment Outcome
2.
J Basic Microbiol ; 50(2): 171-8, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19810046

ABSTRACT

Infections with Mollicutes species (such as Mycoplasma, Acholeplasma, and Ureaplasma) can induce a variety of problems in living organisms and laboratory cell cultures. Therefore, it is necessary to establish a routine diagnostic protocol for Mycoplasma infection in order to ensure reliable research results, as well as the safety of commercial biological products. For that purpose a novel PCR-based procedure using specific designed primers complementary to 16S rRNA genome region of mollicute species was evaluated. PCR was optimized and sensitivity and specificity was evaluated by defined cell count concentrations (2-31250 CFU/ml) of different strains of Mycoplasma, Acholeplasma and Ureaplasma. Amplicon (272 bp) was cloned by PCR-cloning and sequenced by dideoxy chain termination. PCR, was found to be able to detect 10 copies of mollicute target DNA. No cross-reactivity with genomic DNA of non-mollicute bacteria or human cell lines was observed. Forty seven human and animal cell lines were evaluated for mollicute contamination. Twenty five cell lines (53%) were correctly identified as contaminated by this molecular approach. The results of this study demonstrated that this PCR-based method is not only fast and reproducible, but also highly sensitive and specific for detecting contaminant mycoplasmas in cell cultures.


Subject(s)
Acholeplasma/isolation & purification , Bacteriological Techniques/methods , Mycoplasma/isolation & purification , Polymerase Chain Reaction/methods , Ureaplasma/isolation & purification , Acholeplasma/genetics , Animals , Cell Culture Techniques , Cell Line , DNA Primers/genetics , Genes, rRNA , Humans , Mycoplasma/genetics , RNA, Bacterial/genetics , RNA, Ribosomal, 16S/genetics , Sensitivity and Specificity , Ureaplasma/genetics
SELECTION OF CITATIONS
SEARCH DETAIL